1
项与 Virus Activated Killer immune Cells (Binhui Bio) 相关的临床试验An Open Label, Randomized Controlled Clinical Study on the Safety and Efficacy of Virus Activated Killer Immune Cells (VAK) in the Treatment of Malignant Pleural and Peritoneal Effusion
Theory of VAK:
Immune cells (T cells for example) of cancer subjects may be domesticated by the tumor microenvironment, and have low efficacy to kill cancer cells. They could be restimulated by virus antigen, and play a powerful tumor killing role while intrapleural to subjects.
Releasing of tumor-associated antigen could induce specific anti-tumor immune response.
Preparation of VAK:
Separate the immune cells and tumor cells from Malignant Pleural and Peritoneal Effusion.
Incubate the immune cells with inactivated viruses and tumor cells.
Wash to remove impurities.
Intrapleural the immune cells to patients
100 项与 Virus Activated Killer immune Cells (Binhui Bio) 相关的临床结果
100 项与 Virus Activated Killer immune Cells (Binhui Bio) 相关的转化医学
100 项与 Virus Activated Killer immune Cells (Binhui Bio) 相关的专利(医药)
100 项与 Virus Activated Killer immune Cells (Binhui Bio) 相关的药物交易